REFERENCES
- Adler SN, Lyon DT, Sullivan PD. Adenocarcinoma of the small bowel clinical features, similarity to regional enteritis, and analysis of 338 documented cases. Am J Gastroenterol 1982; 77: 326–30.
- Lai EC, Doty JE, Irving C, et al. Primary adenocarcino-ma of the duodenum: analysis survival. World J Surg 1988; 12: 695–9.
- Koretz MJ, Graham R. Primary adenocarcinoma of the jejunum. Am Surg 1989; 55: 539–42.
- Sakker S, Ware CC. Carcinoma of the duodenum: com-parison of surgery radiotherapy and chemotherapy. Br J Surg 1973; 60: 867–72.
- Yeung RS, Weese JL, Hoffman JP, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. Cancer 1993; 72: 2124–33.
- Jigyasu D, Bedikian AY, Stroehlein JR. Chemotherapy for primary adenocarcinoma of the small bowel. Cancer 1984; 53: 23–5.
- Crawley C, Ross P, Norman A, et al. The Royal Marsden experience of small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. Br J Cancer 1998; 78 (4): 508–10.
- Polyzos A, Bramis J, Delladetsima JK, Sfikakis PP. Prolonged survival in metastatic adenocarcinoma of the small intestine treated with irinotecan. Clin Drug Invest 1999; 18 (1): 79–83.
- Rothenberg ML. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol 1998; 25 (5 Suppl. 11): 39-46.
- Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-82.
- Stevnsner T, Bohr VA. Studies on the role of topoiso-merases in general, gene and strand specific DNA repair. Carcinogenesis 1993; 14: 1841–50.
- Tsao YP, Russo A, Nyamuswa G, et al. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell free SV 40 DNA replication sys-tem. Cancer Res 1993; 53: 5908-14.
- Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluo-rouracil-based chemotherapy. J Clin Oncol 1997; 15: 251–60.
- Rothenberg ML, Kuhn JG, Burris III HA, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11: 2194-204.
- Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carci-noma. J Clin Oncol 1997; 15: 2910–9.
- Van Cutsem E, Bajetta E, Niederle N, et al. A phase III multicenter randomized trial comparing CPT-11 to infusional 5Fu regimen in patients (pts) with advanced colorectal cancer (ACRC) after 5FU failure [abstract no. 984]. Proc Am Soc Clin Oncol 1998; 17: 256a.
- Cunningham D, Pyrhonen S, James RD, et al. A phase III multicenter randomized study of CPT-11 versus sup-portive care (SC) alone in patients with 5Fu-resistant metastat-ic colorectal cancer (MCRC) [abstract no. 1]. Proc Am Soc Clin Oncol 1998; 17.
- Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 709–15.
- Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluo-rouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905–14.